Clinical trial · Interventional
Pediatric Long-Term Follow-up and Rollover Study
An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib)
NCT03975829CI-TRIAL-00124078active not recruitingPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A roll-over study to assess long-term effect in pediatric patients treated with dabrafenib and/or trametinib.
Conditions
Conditions (23)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anaplastic Astrocytoma | Anaplastic Astrocytoma | CURATED_BROADER | 0.80 |
| Anaplastic Ganglioglioma | Anaplastic Ganglioglioma | ONTOLOGY_EXACT | 0.98 |
| Anaplastic Oligodendroglioma | Anaplastic Oligodendroglioma | CURATED_BROADER | 0.80 |
| Anaplastic Pleomorphic Xanthoastrocytoma | Anaplastic Pleomorphic Xanthoastrocytoma | ONTOLOGY_EXACT | 0.98 |
| Angiocentric Glioma | Angiocentric Glioma | ONTOLOGY_EXACT | 0.98 |
| Astrocytoma | Astrocytoma | CURATED_BROADER | 0.80 |
| Central Neurocytoma | Central Neurocytoma | ONTOLOGY_EXACT | 0.98 |
| Cerebellar Liponeurocytoma | Cerebellar Liponeurocytoma | ONTOLOGY_EXACT | 0.98 |
| Chordoid Glioma of Third Ventricle |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| dabrafenib | Drug | Dabrafenib | ALIAS |
| trametinib | Drug | Trametinib | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Dabrafenib and/or trametinib
- description
- Patients in this study may receive one of the following treatments received in the parent study which are: * Patients who received monotherapy of either of dabrafenib or trametinib * Patients who received combination of dabrafenib and trametinib * Patients who discontinued treatment on parent study are still offered to participate in long-term follow-up
- interventionNames
- Drug: dabrafenib
- Drug: trametinib
Primary outcomes (1)
- measure
- Number of participants with Adverse Events and Serious Adverse Events (SAEs)
- timeFrame
- Baseline up to approximately 7 years
- description
- To assess the long-term safety of treatment with dabrafenib, trametinib or the combination.
Secondary outcomes (6)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 1 Year
- Maximum age
- 99 Years
Show eligibility criteria text
Key Inclusion Criteria: All Subjects: * Written informed consent, according to local guidelines, signed by the subjects and/or by the parents or legal guardian prior to any study related screening procedures are performed. * Participation in a Novartis sponsored study such as CTMT212X2101, CDRB436G2201, CDRB436A2102, regardless of current age. * Parent study (or cohort of parent study) is planned to be closed. * Subject has demonstrated compliance, as assessed by the investigator, within the parent study protocol requirement(s). * Willingness and ability to comply with scheduled visits, treatment plans and any other study procedures. For Subjects Entering the Treatment Period: * Subject is currently receiving treatment with dabrafenib/trametinib monotherapy or combination within a Novartis Sponsored Drug Development study. Note that subjects who were on the chemotherapy arm of the CDRB436G2201 study are eligible for treatment period of this study only after crossing over into the experimental treatment arm of the CDRB436G2201 study * In the opinion of the investigator is likely to benefit from continued treatment. Key Exclusion Criteria: All Subjects: \- Subject has participated in a combination trial where dabrafenib and/or trametinib was dispensed in combination with another study medication. For Subjects Entering the Treatment Period: * Subject has permanently discontinued from study treatment in the parent protocol due to any reason. * Treatment with dabrafenib and/or trametinib for the subject's indication is approved for marketing and the appropriate dosage form is commercially available and reimbursed in the local country * Subject currently has unresolved drug related severe toxicities for which dabrafenib and/or trametinib dosing has been interrupted in the parent study. If the subject should meet criteria to resume treatment on the parent protocol then they may be eligible for treatment in this study. Other protocol-defined inclusion/exclusion may apply.
References
Publications (0)
Data not yet available
No reference posted for this study.